莫西沙星的综合临床评估：回顾性研究。
Comprehensive clinical evaluation of moxifloxacin: A retrospective study.
机构信息
Pharmacy Intravenous Admixture Services, Weifang People's Hospital, Wefang, China.
出版信息
Medicine (Baltimore). 2023 Jun 2;102(22):e33896. doi: 10.1097/MD.0000000000033896.
The objective was to provide a basis for the rational clinical application of moxifloxacin through its comprehensive clinical evaluation, and to serve as a reference for the clinical comprehensive evaluation of relevant drugs in the future. We obtained data from 91 community-acquired pneumonia patients admitted to Weifang people's hospital from April 2020 to November 2021, including 46 in the evaluation group and 45 in the control group. Based on the requirements of the "Guidelines for the Management of Comprehensive Clinical Evaluation of Drugs" (for trial implementation), systematic evaluations are conducted in terms of drug safety, effectiveness, economy, innovation, suitability, and accessibility. The incidence of adverse drug reactions was low, drug quality, safety and stable efficacy; treatment efficiency was 91.3% and 93.3%, respectively (P > .05); the average total cost of the evaluation group was 9765.28RMB and 10250.69RMB, respectively; efficient cost-effectiveness ratio was 104.67 and 112.52 and cost-effectiveness ratio was 242.71. The economy of the evaluation group had a low price and was highly available.
目的通过综合临床评价为莫西沙星的合理临床应用提供依据，并为今后相关药物的临床综合评价提供参考。我们从 2020 年 4 月至 2021 年 11 月获得了 91 例在潍坊人民医院就诊的社区获得性肺炎患者的数据，其中评估组 46 例，对照组 45 例。基于《药物综合临床评价管理规范（试行）》的要求，从药物安全性、有效性、经济性、创新性、适宜性和可及性等方面进行了系统评价。不良反应发生率低，药物质量安全稳定疗效；治疗有效率分别为 91.3%和 93.3%（P>.05）；评估组的平均总费用分别为 9765.28 元和 10250.69 元；有效成本效益比分别为 104.67 和 112.52，成本效益比为 242.71。评估组的经济性具有价格低廉、可用性高的特点。
Zotero 插件